Shionogi, Purdue launch OIC drug Symproic in the U.S.

In October, Shionogi & Co. Ltd. (Tokyo:4507) and Purdue Pharma L.P. (Stamford, Conn.) launched Symproic naldemedine (S-297995) in the U.S. to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment which does not require frequent opioid dosage escalation. Purdue has rights to co-commercialize the oral peripheral mu opioid receptor (MOR; OPRM1) antagonist in the U.S. (see BioCentury, Dec. 30, 2016)...